Neurophysiological Study on DBS in OCD Patients to Inform Neuromodulation Strategies
A clinical trial is underway to investigate the neurophysiological mechanisms in OCD patients using deep brain stimulation (DBS) with Medtronic's technology.
Phase III
Neurology / Obsessive-Compulsive Disorder (OCD)
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
This clinical trial is pivotal as it explores the neurophysiological mechanisms of OCD treatment through deep brain stimulation, potentially leading to enhanced therapeutic strategies. The findings could significantly influence the competitive landscape in neuromodulation therapies for OCD.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor patient outcomes and neurobehavioral data at key timepoints, particularly post-DBS activation at 2 weeks, 3 months, and 6 months.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.